IGF - I

  • 文章类型: Journal Article
    肢端肥大症是一种罕见的内分泌疾病,由垂体腺瘤的生长激素(GH)分泌过多引起。GH水平升高会刺激胰岛素样生长因子1(IGF-1)的过量产生,从而导致临床表现的隐匿发作。最常见的原发性中枢神经系统(CNS)肿瘤,脑膜瘤起源于脑膜的蛛网膜层,通常是良性和缓慢生长的。脑膜瘤在女性中的发病率是男性的两倍多,年龄调整后的发病率(每100,000人)分别为10.66和4.75。一些报告描述了脑膜瘤和肢端肥大症的同时发生。我们的目的是确定肢端肥大症患者患脑膜瘤的风险是否升高。对文献的调查表明,垂体腺瘤和脑膜瘤的同时发生是一种罕见的现象,大多数病例涉及GH分泌腺瘤。据我们所知,从未对脑膜瘤与GH水平升高(由于肢端肥大症中的GH分泌腺瘤或暴露于外源性GH)之间的关系进行过系统评价.所观察到的肢端肥大症和脑膜瘤之间共存的性质-无论是反映因果关系还是仅仅是共同关联-尚不清楚。病理生理学病因也是如此。
    https://www.crd.约克。AC.英国/普华永道/,标识符CRD42022376998。
    Acromegaly is a rare endocrine disorder caused by hypersecretion of growth hormone (GH) from a pituitary adenoma. Elevated GH levels stimulate excess production of insulin-like growth factor 1 (IGF-1) which leads to the insidious onset of clinical manifestations. The most common primary central nervous system (CNS) tumors, meningiomas originate from the arachnoid layer of the meninges and are typically benign and slow-growing. Meningiomas are over twice as common in women as in men, with age-adjusted incidence (per 100,000 individuals) of 10.66 and 4.75, respectively. Several reports describe co-occurrence of meningiomas and acromegaly. We aimed to determine whether patients with acromegaly are at elevated risk for meningioma. Investigation of the literature showed that co-occurrence of a pituitary adenoma and a meningioma is a rare phenomenon, and the majority of cases involve GH-secreting adenomas. To the best of our knowledge, a systematic review examining the association between meningiomas and elevated GH levels (due to GH-secreting adenomas in acromegaly or exposure to exogenous GH) has never been conducted. The nature of the observed coexistence between acromegaly and meningioma -whether it reflects causation or mere co-association -is unclear, as is the pathophysiologic etiology.
    UNASSIGNED: https://www.crd.york.ac.uk/prospero/, identifier CRD42022376998.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    Ghrelin广泛存在于中枢神经系统和外周器官中,并具有生物活性,如维持能量稳态,调节脂质代谢,细胞增殖,免疫反应,胃肠生理活动,认知,记忆,昼夜节律和奖励效应。在许多良性肝脏疾病中,它可能对脂肪变性起到保肝作用,慢性炎症,氧化应激,线粒体功能障碍,内质网应激与细胞凋亡,改善肝细胞自噬和免疫反应,改善疾病进展。然而,Ghrelin在肝包虫病中的作用目前尚不清楚.本文系统地总结了Ghrelin调节肝脏生长代谢的分子机制,免疫炎症,纤维发生,增殖和凋亡,以及它在肝纤维化疾病中的保护作用,并进一步提出Ghrelin在肝棘球蚴感染中的作用。在感染过程中,它可能通过改善免疫炎症微环境和纤维化状态来促进寄生虫在宿主上的寄生和存活,从而加速疾病进展。然而,目前缺乏针对这一观点的靶向体外和体内实验证据。
    Ghrelin widely exists in the central nervous system and peripheral organs, and has biological activities such as maintaining energy homeostasis, regulating lipid metabolism, cell proliferation, immune response, gastrointestinal physiological activities, cognition, memory, circadian rhythm and reward effects. In many benign liver diseases, it may play a hepatoprotective role against steatosis, chronic inflammation, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress and apoptosis, and improve liver cell autophagy and immune response to improve disease progression. However, the role of Ghrelin in liver Echinococcosis is currently unclear. This review systematically summarizes the molecular mechanisms by which Ghrelin regulates liver growth metabolism, immune-inflammation, fibrogenesis, proliferation and apoptosis, as well as its protective effects in liver fibrosis diseases, and further proposes the role of Ghrelin in liver Echinococcosis infection. During the infectious process, it may promote the parasitism and survival of parasites on the host by improving the immune-inflammatory microenvironment and fibrosis state, thereby accelerating disease progression. However, there is currently a lack of targeted in vitro and in vivo experimental evidence for this viewpoint.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    生长激素(GH)治疗可以追溯到1958年,尽管在短期内表现出了很好的安全性,从未停止过对潜在长期副作用的担忧。在过去的十年里,在儿童期接受GH治疗的年轻成年患者的不同队列中,许多观察性研究得出的结果相互矛盾.注意力主要集中在与GH治疗相关的三个主要潜在风险:癌症,心脑血管疾病和糖尿病。这篇综述旨在提供主要研究的详细概述,这些研究报告了儿童期接受rhGH治疗的受试者的长期安全性。强调支持或反对癌症风险的证据,心脑血管疾病和糖尿病。
    Growth hormone (GH) therapy dates back to 1958 and, though has shown an excellent safety profile in the short-term, has never ceased to raise concern about potential long-term side effects. In the last decade, a number of observational studies in different cohorts of young adult patients treated with GH during childhood have yielded conflicting results. The attention has mainly focused on three major potential risks associated with GH therapy: cancer, cardio and cerebrovascular diseases and diabetes. This review intends to provide a detailed overview of the main studies reporting long-term safety in subjects treated with rhGH therapy during childhood, highlighting the evidence for or against the risk of cancer, cardio and cerebrovascular diseases and diabetes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号